Your session is about to expire
← Back to Search
Durvalumab + Chemotherapy for Ovarian Cancer
Study Summary
This trial is studying a combination of drugs as a possible treatment for ovarian, primary peritoneal, or fallopian tube cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't received any treatment for my advanced ovarian, peritoneal, or fallopian tube cancer.I have had an autoimmune disease in the last 2 years.You have a history of a weak immune system since birth.You have had a bad reaction to durvalumab or any of its ingredients in the past.I haven't taken strong immune system suppressing drugs in the last 28 days, except for low-dose steroids or inhalers.I am willing and able to follow the study's requirements, including treatments and visits.I have received an organ from another person.I have had cancer spread to the lining of my brain and spinal cord.I have not received a live vaccine within 30 days before joining the study or before getting durvalumab.I have a tumor sample available for research before any treatment.I do not have any severe illnesses that my doctors are still trying to get under control.I have been diagnosed with tuberculosis in the past.I have seizures that are not controlled by medication.I am scheduled for chemotherapy with carboplatin and paclitaxel.I am not pregnant, breastfeeding, and I use birth control if I can have children.Your hemoglobin level is 9 grams per deciliter or higher.You have a detectable disease that can be measured using specific criteria.I am fluent in English.I don't have lasting side effects from cancer treatment above mild level.My cancer is a high-grade type that started in the ovary, peritoneum, or fallopian tube.Your AST and ALT levels in your blood should be within a certain range, unless you have cancer that has spread to your liver, in which case they can be slightly higher.I am fully active or restricted in physically strenuous activity but can do light work.You are expected to live for at least 12 more weeks.My cancer is either mucinous or a low-grade epithelial type.I have brain metastases that need treatment.I have little to no nerve damage from my treatment.I am allergic to paclitaxel, carboplatin, or their ingredients.Your platelet count is at least 100,000 per cubic millimeter.Your bilirubin levels in the blood are not higher than the normal range set by the hospital.Your heart's electrical activity takes too long to reset between beats, which could be a problem for the study.Your body has enough infection-fighting white blood cells.I have or had Crohn's disease or ulcerative colitis.I have had treatment for ovarian, fallopian tube, or peritoneal cancer.I am set to have surgery to remove my tumor after 3 rounds of chemotherapy.I have not been treated with PD1 or PD-L1 inhibitors, including durvalumab.My kidneys are functioning well enough to clear waste.
- Group 1: Treatment (durvalumab, carboplatin, paclitaxel, questionnaire)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any preceding research initiatives regarding Durvalumab?
"At this time, there are 1432 clinical trials that utilize Durvalumab as a form of treatment. 365 of these studies have advanced to Phase 3 status. The majority of the research centers distributing this drug are located in Shanghai; however, 74621 sites all over the world currently support its use."
Are there vacancies available in this medical experiment?
"Notwithstanding clinicaltrials.gov, this particular medical trial has ceased recruiting patients; the protocol was initially posted on July 6th 2016 and last updated on June 24th 2022. However, 2052 other trials are currently enrolling participants at the moment."
What is the ceiling of participants in this medical trial?
"This medical trial is no longer recruiting any new candidates. Initially posted on the 6th of July, 2016 and last edited on 24 June 2022, alternative studies with stage iv ovarian cancer ajcc v6 and v7 or Durvalumab as potential interventions are available; 620 trials for the former and 1432 for the latter are presently accepting participants."
What applications of Durvalumab have been documented?
"Durvalumab is typically used for palliative therapy, but it may also be effective in the management of malignant peritoneal neoplasms and other related diseases."
Share this study with friends
Copy Link
Messenger